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Abstract
The number of conditions included in newborn screening panels has increased rapidly in the 
United States during the past decade, and many more conditions are under consideration for 
addition to state panels. The rare nature of candidate conditions for newborn screening makes their 
evaluation challenging. The scarcity of data on the costs of screening, follow-up, treatment, and 
long-term disability must be addressed to improve the evaluation process for nominated 
conditions. Decision analyses and economic evaluations can help inform policy decisions for 
newborn screening programs by providing a systematic approach to synthesizing available 
evidence and providing projected estimates of long-term clinical and economic outcomes when 
long-term data are not available. In this review, we outline the types of data required for the 
development of decision analysis and cost-effectiveness models for newborn screening programs 
and discuss the challenges faced when applying these methods in the arena of newborn screening 
to help inform policy decisions.
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The U.S. Department of Health and Human Services Secretary’s Advisory Committee on 
Heritable Disorders in Newborns and Children (SACHDNC) makes recommendations for 
conditions to be included in the recommended uniform newborn screening panel.1 The 
activities of the Advisory Committee are supported by an external evidence review 
workgroup. This external evidence review group conducts systematic reviews summarizing 
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available information on the benefits and harms of screening for nominated conditions.1–6 
As part of this process, the evidence review group has conducted several reviews of 
candidate disorders. Although the group searched for cost-effectiveness analyses or sources 
of evidence that could be used to develop decision analysis or cost-effectiveness models of 
screening for these disorders, rarely were such studies identified.1–6 Certain coauthors 
(L.A.P., A.R.K., J.M.P.) participate in this evidence review group. Other coauthors have 
previously addressed the advantages and challenges to using cost-effectiveness analysis to 
inform newborn screening policy decisions (S.D.G.)7,8 and to address ethical issues relating 
to newborn screening (B.A.T.).9,10
This review describes the types of data and data elements required to develop decision 
analytic models and conduct economic evaluations of newborn screening programs. This 
review is intended as a resource for researchers designing studies to evaluate the clinical and 
economic outcomes for newborn screening programs and to aid reviewers of decision 
analytic models and economic evaluations of newborn screening programs. Decision 
analysis can provide an approach for synthesizing evidence from disparate sources to assist 
decision makers in estimating potential long-term health benefits and harms. Cost-
effectiveness analysis can provide information on the relative value of screening for a 
condition or set of conditions.
DECISION ANALYTIC MODELING
Decision analysis is a systematic approach to decision making under conditions of 
uncertainty that has been applied to clinical and public health problems.11 Decision analytic 
models can be used to simulate randomized clinical trials for new health interventions, to 
project beyond the clinical trial time frame, or to compare treatment protocols not directly 
compared in head-to-head trials. The decision analytic approach allows the decision maker 
to identify which alternative is expected to yield the most health benefit. It can also allow 
analysts to characterize the uncertainty associated with projections of clinical and economic 
outcomes over the long term,12 which is important given the lack of long-term outcomes 
data for most conditions considered for newborn screening.
To develop a decision analytic model, each aspect of the decision problem requires attention: 
defining of the set of possible alternative methods for disorder identification (e.g., universal 
screening and clinical identification), screening technologies or protocols, possible choices 
regarding timing of implementation (i.e., screening at birth or at a later age), uncertainties 
(e.g., consideration of long-term health outcomes), health outcomes (e.g., disability, death), 
probabilities of these identified outcomes, and the values assigned to each health outcome.13 
The decision analytic modeling approach uses evidence from all available sources, such as 
clinical trials, cohort studies, observational studies, case–control studies, meta-analyses, and 
expert opinion; synthesizes the evidence; and can account for the strength of each evidence 
source by including the range of uncertainty associated with each parameter input.14
For newborn screening policy decisions, a decision analytic approach can leverage existing 
data for clinical and economic outcomes with unpublished data and estimates based on 
expert opinion to provide policy-relevant information. Given the rare nature of screened 
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conditions, the evidence base to evaluate screening for such conditions is typically sparse. A 
decision analytic modeling approach can be valuable to decision makers by providing 
estimates of long-term outcomes and in identifying the parameters, when varied over ranges 
identified to reflect the uncertainty associated with a parameter input, that have the greatest 
impact on results. By helping identify projected outcomes and key data gaps, decision 
analysis can supplement the available evidence base and also help prioritize further research 
areas.13 This paper provides a brief introduction to the terms of decision analysis; more 
detailed primers are available elsewhere.15–19
ECONOMIC EVALUATION
If a decision analytic model incorporates costs, it becomes an economic evaluation model 
(Table 1). The two main types of economic evaluations in health care are cost-effectiveness 
analysis and cost–benefit analysis. This article focuses on cost-effectiveness analysis, as it is 
more commonly used for evaluating health interventions. Cost–benefit analysis, which 
requires the conversion of health benefits into monetary terms, has been less well-accepted 
by the medical community, with the exception of environmental health applications for 
which the use of cost–benefit analysis is more common.20
Cost-effectiveness analysis is used to measure the relative value of health-care interventions 
in terms of the cost per health benefit gained, such as the cost per child identified with a 
newborn-screened condition or the cost per death averted.21 If health outcomes are measured 
using a preference-based measure, such as quality-adjusted life years, which integrate 
morbidity and mortality, then the analysis is considered to be a cost–utility analysis, a 
special case of cost-effectiveness analysis.20–22 Quality-adjusted life years are calculated by 
multiplying the value for each health state, called a “health utility,” by the duration of the 
health state.23 The “health utility” is scaled between 1.0, which represents perfect health, 
and 0.0, which represents a health state equivalent to being dead, although health states can 
be assigned a value less than zero, which represents a state of health considered as being 
“worse than dead.”22
For newborn screening applications, cost-effectiveness is calculated by dividing the net costs 
by the net health benefits of newborn screening for a disorder, or set of screened disorders, 
as compared with clinical identification of the specified disorder(s), assuming that both the 
numerator and denominator are positive. If the health denominator is negative, the potential 
harms of the screening program outweigh projected health benefits and screening would be 
considered to be “dominated” by clinical identification, and no ratio is calculated. If the 
numerator of net costs is negative, the intervention is said to be cost saving, and no ratio is 
calculated. If net costs are positive, screening does not reduce total costs, but can still be 
considered cost-effective. Most health interventions are not cost saving, but many are cost-
effective.24,25
Screening for most heritable disorders is not cost saving and requires a net investment in 
resources. Exceptions are disorders, such as phenylketonuria, that have a low mortality rate 
and a high lifetime cost of treatment for complications associated with late diagnosis. For a 
given test cost, a lower prevalence of a condition is associated with higher cost per case 
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detected and lower cost-effectiveness. For that reason, multiplex testing, e.g., tandem mass 
spectrometry, is an important strategy to improve the cost-effectiveness of screening for low-
prevalence conditions. Whether screening is considered cost-effective can vary depending on 
the threshold used to define cost-effectiveness.26,27
TYPES OF DATA NEEDED FOR DECISION ANALYTIC MODE LS AND EC 
ONOMIC EVALUATIONS
Required data elements fall into three general categories: clinical outcomes (measures and 
associated probabilities), values, and costs. Figure 1 shows a simplified schematic of a 
decision analytic model. Each health state included in the decision analysis is assigned both 
a probability and a value. This value, also known as a health utility weight, is used to reflect 
the quality of life associated with a health state (described in more detail in the following). 
For a cost-effectiveness analysis, each health state or transition to a health state would also 
be associated with a cost.
Screening and clinical outcomes
Screening phase—Characteristics of screening algorithms include sensitivity and 
specificity of screening protocols and the accuracy of confirmatory testing relative to 
diagnostic evaluation. Reliable data on the sensitivity and specificity of alternative screening 
protocols, such as universal or targeted screening, are needed as inputs for accurate decision 
analytic models and cost-effectiveness analyses. It is also important to characterize detection 
rates for conditions in the absence of screening.
Although newborn screening experts generally seek to maximize sensitivity to avoid missed 
cases, the false-positive rate can significantly affect costs and therefore is relevant in 
evaluating cost-effectiveness. As specificity increases, the number of false-positive test 
results decreases. Therefore, a highly specific screening protocol can improve cost-
effectiveness by reducing the number of children who require short-term follow-up and 
confirmatory testing but are not ultimately diagnosed with the disorder in question. For 
example, the introduction of tandem mass spectrometry for phenylketonuria helped reduce 
costs by increasing test specificity and consequently reduced the number of false-positives 
and associated costs.28 Specificity typically has substantially more influence on costs than 
does sensitivity because of the low incidence of screened conditions. Lower specificity is 
associated with higher costs of follow-up for false-positives, which can be sizeable for a 
screening test with a large number of false-positive results for each true-positive case 
identified. Suppose that sensitivity is reduced from 99.9% to 95%; this would reduce 
identified cases, and associated health outcomes, by ~5%. In contrast, reducing specificity 
from 99.9% to 95% would raise the number of false-positives to 50 times the original 
estimate and the costs of follow-up would rise proportionally.
Medical evaluation phase—Each condition requires specification of a protocol for 
follow-up evaluation that defines sequences of confirmatory or diagnostic testing for 
different out-of-range test results. The results of the diagnostic evaluation may be either 
dichotomous or tiered, e.g., presumptive positive, possible, or negative. For purposes of 
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economic evaluation, the services required for each stage of confirmatory testing need to be 
specified as well as the probabilities of true-positives at each stage.
Clinical outcomes for individuals identified via screening versus clinical 
identification—Defining outcomes for the screening program, clinical identification in the 
absence of screening, and the probability of these outcomes requires data on long-term 
health outcomes, such as data on hospitalization, cognitive function, disability, and 
mortality. One potential bias when measuring screening and clinical outcomes is a failure to 
adjust for differences in the spectrum of severity of cases detected clinically as compared 
with those detected by screening. For many disorders, such as congenital hypothyroidism, 
medium-chain acyl-CoA dehydrogenase (MCAD) deficiency, and cystic fibrosis, screening 
identifies many children with relatively mild phenotypes who would have been less likely to 
be identified in the absence of screening in addition to those with severe phenotypes who 
would have been detected clinically in the absence of screening.29–31 For these disorders, 
using data on the severity of outcomes among clinically identified cases to project outcomes 
in screened cohorts in the absence of screening will overstate the magnitude of morbidity 
and disability prevented by screening.32 An appropriate model design for this situation 
would allow for differing levels of severity in screened and clinically identified cohorts. On 
the other hand, cases of sudden death due to a disorder, such as congenital adrenal 
hyperplasia (CAH) or MCAD deficiency, are likely to be missed in the absence of screening.
33,34 Whether the net effect of both types of bias leads to an underestimate or overestimate 
of the magnitude of mortality risk is dependent on the particular disorder in question.
One particularly challenging task for the development of a decision analytic model for 
newborn screening is the need for accurate data on unscreened cohorts. Using historical data 
on unscreened cohorts who may not have had access to currently available treatments could 
be misleading and result in substantial overestimates of the benefits of screening. An 
appropriate evaluation of a screening program requires that comparable treatments were 
available to both screened and clinically identified cohorts. Such data are rarely available, 
with notable exceptions for cystic fibrosis and MCAD deficiency.35
For example, a long-term study of outcomes in birth cohorts with MCAD deficiency in 
Australia during 1973 to 2002 demonstrated that ascertainment in unscreened cohorts 
improved over time as a result of increased clinical awareness, and the severity of outcomes 
diminished with increased clinical awareness. 36 In particular, for births during 1995 to 
2002, there were no cases of intellectual disability in unscreened cohorts with MCAD 
deficiency.36 Also, the authors adjusted downward the estimates of the frequency of 
mortality among clinically diagnosed children in unscreened cohorts born during 1994 to 
2002 to reflect a lower risk of death in asymptomatic cases missed without screening.37 At 
the population level, the net effect of ascertainment bias outweighed the opposite bias of 
missed diagnoses of sudden death among undiagnosed children.35
Another example of the implications of using historical data on unscreened cohorts is CAH. 
The key outcome used to evaluate the effectiveness of newborn screening for CAH is 
prevention of death associated with adrenal crises. Previous analyses of screening for CAH 
relied on clinical data from populations without adequate treatment.38 Available data from 
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high-income countries indicate a low level of mortality associated with unscreened CAH, 
even taking into account the missed cases.33,39 As a consequence, economic evaluations that 
use historical estimates of mortality associated with unscreened CAH will likely 
overestimate the cost-effectiveness of screening for CAH in such countries.38 On the other 
hand, screening has benefits besides prevention of death, such as the prevention of 
morbidity.
Effectiveness of treatment for identified individuals—Estimates of treatment 
effectiveness for both short- and long-term clinical end points are needed. Long-term 
outcomes are of key importance for defining the effectiveness of an intervention and will, as 
a result, be of key importance for determining cost-effectiveness. For example in 1999, 
Denmark introduced newborn screening for congenital toxoplasmosis based on evidence of 
favorable short-term outcomes associated with treatment. However, in 2007, after data on 
long-term outcomes revealed no evidence of lasting benefit, Denmark discontinued 
screening for congenital toxoplasmosis.40 Estimates of long-term adherence and adverse 
events associated with recommended treatments are required and should include the full 
spectrum of possible outcomes, along with their associated costs and intended and 
unintended consequences.
Cost inputs
In the United States, newborn screening programs are public health programs funded at the 
state level. For most public programs, the societal perspective is the most appropriate 
analytic perspective to assume for an economic evaluation because this perspective is the 
most comprehensive analytic perspective and will include all direct medical costs, direct 
nonmedical costs (e.g., transportation), and opportunity costs (e.g., patient or family time 
costs associated with screening, follow-up, and care).21 This review assumes the use of the 
societal perspective for costs. Costs can be separated into several subcategories: those 
relating to the costs of screening, treatment, and short- and long-term costs of care for the 
identified condition (Table 2). The costs of a newborn screening program will include the 
downstream costs of care as well as the costs of the initial screen, follow-up testing, and 
diagnosis.
Screening phase—The initial screening test represents only a subset of the total costs 
associated with a newborn screening program. The costs associated with this screening 
phase involve more than the cost of performing the initial screening test. It also includes the 
costs associated with reporting positive or uncertain results and the collection of repeat 
specimens and repeated screens, if necessary.
Currently, there are few published data on the costs of newborn screening programs. Each 
state has its own set of screened conditions and processes for conducting screening. States 
vary in the number of specimens collected per infant, with 12 states routinely collecting and 
testing two specimens for each infant. States vary greatly in the extent to which they fund 
follow-up testing, particularly long-term follow-up, as well as genetic counseling and 
cascade testing of family members. The substantial variation across states and sharing of 
resources across other public health programs can make tracking the costs specific to a 
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newborn screening program difficult. Also, testing costs vary according to the annual 
number of specimens tested in a laboratory because of economies of scale, which can result 
in more than a threefold difference in average testing costs for a given disorder.38 
Commonly, cost-effectiveness analyses assign testing cost based on data from just one state, 
which does not adequately reflect variability across states, therefore limiting the ability to 
draw generalizable conclusions.
Medical evaluation phase—When a positive newborn screening result occurs, a number 
of costs accrue related both to additional testing and to medical evaluation of the infant. For 
example, an infant with a positive result will undergo confirmatory or diagnostic testing and 
medical evaluations by one or more physicians (e.g., primary-care, specialist) depending 
upon the complexity of the workup or the emergent nature of the evaluation. These costs will 
include direct medical costs for diagnostic tests and clinician fees as well as time and 
transportation costs for patients and their families. Many economic analyses oversimplify 
this process by assuming fixed costs for positive specimens. In reality, the type of tests 
ordered and the urgency with which the infant is brought in for testing, both of which affect 
costs, often vary based on the amount by which the test result exceeds the screening cutoff 
and will vary by disorder.
Costs of care for individuals identified via screening or clinical identification
—Downstream costs of screening include the net costs of medical care and treatment for a 
screened individual as compared with what the costs would have been in the absence of 
screening. Direct medical costs for hospitalizations, procedures, drug treatments, outpatient 
visits, medical equipment, and rehabilitation may differ. For example, additional costs of 
caring for patients with MCAD deficiency detected through screening could include the 
costs of additional medical visits, preventive hospitalizations to avoid fasting for MCAD 
deficiency infants with other illnesses, possible costs of carnitine supplementation, and 
parent time costs. Preventive treatment could reduce costs associated with treating metabolic 
crises and their disabling sequelae, including special education and caregiving costs. 
Whether net medical costs associated with screening for a given disorder are positive or 
negative is difficult to reliably predict. In the case of MCAD deficiency, an Australian study 
found little overall difference in costs of hospitalizations whether or not screening was 
performed,41 contrary to other published economic analyses.42
For patients identified with severe combined immunodeficiency, costs of caring for 
identified children would include costs associated with the receipt of interventions such as 
hematopoietic stem cell transplant as well as costs of possible adverse events associated with 
hematopoietic stem cell transplant and costs of infections if treatment is not perfectly 
effective. 43 For severe combined immunodeficiency patients identified through clinical 
identification, categories of costs would largely be the same, including costs of 
hematopoietic stem cell transplant, adverse events, and infections, but the number of 
infections and their associated morbidity and mortality would be greater under clinical 
identification because of the lower effectiveness of hematopoietic stem cell transplant in 
preventing infections among clinically identified individuals.
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Valuation of health outcomes
With newborn screening, changes in health-related quality of life can be associated with 
screening test results, differences in health states for the screened disorder, and 
recommended treatments, such as transplants or dietary restrictions. For an economic 
evaluation, health utilities should be assigned to each health outcome. Both direct and 
indirect methods are available for valuing health outcomes.44
The valuation of health outcomes for newborn-screened conditions presents a number of 
challenges for researchers. Methodological challenges of valuing children’s health states 
include the need for proxy respondents, lack of validated methods for valuing health in 
young children, and the need for the inclusion of spillover effects on family members’ 
quality of life.45,46 Another challenge for valuing health outcomes related to newborn-
screened conditions is the lack of data on long-term outcomes, such as the effect of a 
condition on employment or educational attainment. For many conditions, information on 
long-term health outcomes is scarce, which makes it difficult to assign values to outcomes 
that are not well described. The rarity of the conditions makes it difficult to employ indirect 
methods of valuation, in which a patient (or in this case the parent proxy) would rate the 
condition using a predefined set of health attributes.
This specific set of challenges has resulted in substantial variability in health utilities used in 
existing cost–utility analyses of newborn screening programs. A recent review of cost–utility 
analyses of newborn screening for metabolic disorders found a high level of variability in the 
specific weights assigned to the same conditions.47 For example, serious intellectual 
disability was assigned weights in the different studies ranging from 0.06 (equivalent to 
being close to death) to 0.67.47
Conventionally, only the loss of health utility for the affected individual is included in 
quality-adjusted life year estimates, but the inclusion of spillover effects on the quality of 
life of other family members is gaining recognition as an important component of economic 
evaluations, especially for childhood health conditions.45 Economic evaluations of 
children’s health should consider the relevance of family spillover effects, defined as the loss 
in health-related quality of life for a parent or caregiver due to a child’s condition. We are 
aware of only one newborn screening economic evaluation that has incorporated family 
spillover effects by asking parents to calculate losses in health-related quality of life for both 
their children and themselves.48 In practical terms, the dominant sources of quality-adjusted 
life year gains from newborn screening are from the prevention of morbidity and mortality 
in the newborn. Future research should focus on improving consistency and accuracy of 
measuring health outcomes for newborn-screened conditions, regardless of whether family 
spillover effects are included.
POLICY-RELEVANT OUTCOMES
A decision analytic model of newborn screening strategies can provide short- and long-term 
estimates of the outcomes important to policy decisions for newborn screening programs. 
Policy makers have considered outcomes, such as expected numbers of infant and child 
deaths prevented, cases of permanent disability avoided, and changes in health-care costs, in 
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the criteria that have been used to assess newborn screening tests in the United States.49 
Decision analytic models can also provide projections of testing-related outcomes, such as 
expected numbers of positive and false-positive screens, and utilization-related outcomes, 
including expected hospitalizations, procedures, and outpatient visits, as well as the cost-
effectiveness of alternative screening strategies. This comprehensive set of testing-related 
outcomes is likely to be valuable in weighing the evidence for policy decisions and newborn 
screening.
CHALLENGES AND OPPORTUNITIES
Conducting high-quality decision analyses and economic evaluations requires high-quality 
evidence for all of the aforementioned areas: health outcomes, costs, and quality of life. Data 
limitations can be challenging for any health application, given the many categories of 
evidence required, but these data limitations are particularly salient for newborn screening 
candidate disorders due to the low incidence and the long time frame over which outcomes 
need to be considered. Constructing a decision analytic model and assembling the necessary 
inputs can be resource intensive and time consuming, which can present an additional 
challenge when the need for a policy decision is urgent.
Lack of data on long-term outcomes
The key data challenge for measuring health outcomes is the absence of data on long-term 
outcomes of newborn screening programs. More data are becoming available for short-term 
outcomes of newborn screening programs, such as the sensitivity and specificity of 
screening protocols. As long-term follow-up programs become established, the increasing 
availability of long-term data for screened conditions can potentially help inform decisions 
about candidate conditions that share similar characteristics. However, such research efforts 
are not likely to address the unique challenge of assessing what long-term outcomes would 
be in the absence of screening. The advantage of a decision analytic modeling approach is 
that a range of assumptions for outcomes of clinically identified cohorts can be explored in 
the analysis.
Decision analysis represents a promising approach to evaluating newborn screening policy 
options. The use of decision analytic models can assist decision makers by providing 
estimates of health benefits and possible risks for varying time horizons and for varying 
assumptions for test characteristics, treatment benefits, and possible harms. Understanding 
the ranges of possible outcomes for different input assumptions can be informative to 
decision makers, given the absence of long-term data for most conditions that are nominated 
for newborn screening. A decision analysis can consider a range of assumptions for key 
issues such as a broader spectrum of disease detected by screening or potential harms of 
treatment.
Difficulties in defining costs
There are numerous challenges to obtaining a full account of the costs associated with a 
newborn screening program. Most of the available data are from the health-care system 
perspective. However, because state-level newborn screening programs are public programs, 
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the appropriate perspective to use in most cases would be the societal perspective. Some 
analyses have used the payer perspective; however, given the substantial burden of many of 
these conditions on family members, alternative perspectives such as the payer perspective 
could result in substantial underestimation of the burden of illness and associated benefits of 
averted illness. In these more narrow analytic perspectives, some of the types of costs listed 
earlier, such as patient or family time costs, would be excluded.21 An additional challenge to 
the collection of accurate cost data in the United States is the fragmented structure of health-
care financing in which costs are covered by various payers, including state public health 
programs, public and private health payers, and the family.
Even more challenging is the estimation of costs for clinically identified cases. Because 
identification and treatment may have improved over time, the use of historical data for 
clinically identified cases may be misleading. For the comparator strategy of clinical 
identification, the appropriate approach for an economic evaluation should assume usual 
care from the same time period. Treatment patterns are likely to represent a substantial 
improvement when compared to historical data from prior to the initiation of newborn 
screening. For example, the two classic examples of newborn screening programs that are 
cost saving are phenylketonuria and congenital hypothyroidism. 50 However, the magnitude 
of reduction in costs has likely been overstated in published economic evaluations because 
of widespread misinterpretation of available data on long-term outcomes in unscreened 
cohorts for these two disorders. Longterm outcomes for patients with late-treated 
phenylketonuria show that the degree of cognitive impairment on average is less than was 
assumed in previously published economic evaluations. 50
Identifying data for the comparator strategy
The comparator strategy is the alternative against which a new screening policy is compared. 
Choice of the comparator can affect conclusions about the cost-effectiveness of screening. 
For example, the comparator strategy for universal screening could be either targeted 
screening or no screening. Targeted screening is generally difficult to use as a comparator 
because of a lack of information about the effectiveness and costs of targeted versus 
universal screening. However, considering alternative screening strategies is one advantage 
of using a decision analytic approach, allowing for the consideration of alternatives for 
which little data are available.
Valuation of health outcomes
The valuation of health outcomes using health utilities for newborn screening presents 
methodological challenges due to a lack of standardization regarding optimal approaches for 
assigning health utilities to child health outcomes.45,47 Improved methods for valuing 
children’s health conditions needs to be paired with better characterization of long-term 
outcomes to provide inputs appropriate for decision analytic modeling and economic 
evaluation.
Defining the scope of the analysis
Calculating the cost-effectiveness of screening for a single condition may not be 
straightforward. If the out-of-range value could be associated with more than one condition, 
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then it may be more appropriate to evaluate the cost-effectiveness of screening for the panel 
of conditions instead of the single condition being added to the panel and then evaluating the 
incremental cost-effectiveness of the expanded panel as compared with the original panel. 
These other conditions are referred to as “secondary targets.” This situation is not unique to 
newborn screening and is analogous to other screening protocols for which the reported 
results can include incidental findings unrelated to the original screening condition. If these 
findings are reported and followed up on, these must also be included in the cost-
effectiveness analysis. In the case of newborn screening, this requires the analyst to 
explicitly and carefully define the scope of the analysis.
FUTURE CONSIDERATIONS
Decision analyses and cost-effectiveness analyses of newborn screening programs require 
data on short-term screening results and long-term outcomes. Analyses of other types of 
screening programs, such as mammography for breast cancer or colonoscopy for colon 
cancer, can provide instruction for the analysis of newborn screening programs. Such 
previous analyses of screening and public health programs demonstrate the value of decision 
analytic modeling to help inform clinical and public health decisions for which long-term 
data are not available.12 In the case of newborn screening, parameters that are characterized 
using limited data can be assessed for their relative impact on outcomes using sensitivity 
analysis; a decision analytic approach could help prioritize research areas by identifying 
which parameters have the most effect on projected outcomes.13 Over the long term, the use 
of decision analytic modeling, along with increased primary data collection, could optimize 
the use of existing data on newborn screening programs. Decision analytic modeling also 
provides an opportunity to model alternative strategies in addition to universal screening and 
clinical identification, such as targeted screening, and can provide results on alternative 
strategies based on a combination of the best available evidence in the absence of direct 
clinical trials.
Specific findings from decision analytic models of newborn screening can provide useful 
insights. For example, a recent analysis of newborn screening for MCAD deficiency 
demonstrated that assumptions about the loss in quality of life associated with dietary 
treatment were potentially influential on cost-effectiveness results,48 and this finding could 
potentially apply to other conditions.
The collection of long-term data on health outcomes, costs, and quality of life should be 
incorporated into current efforts to create registries and collect data for conditions 
identifiable through newborn screening, including those on the recommended universal 
newborn screening panel. States and regional collaboratives can play a role in collecting 
these data. For example, the National Newborn Screening Translational Research Network is 
developing standards for how such data can be efficiently collected through a standard 
database platform. The Network is testing this approach in pilot studies of screening for 
lysosomal storage disorders. In addition to outcomes data from a screened cohort, it is 
necessary to have comparable information on long-term outcomes of a representative 
unscreened cohort for the development of a decision analytic model. This information may 
be derived either from population-based surveillance in populations without screening or 
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from retrospective screening studies of stored dried blood specimens collected prior to the 
initiation of screening for the disorder(s) of interest.51 Both study designs have been applied 
in the case of MCAD deficiency.37,52 The creation and maintenance of registries and related 
data collection efforts will require resources; ongoing funding from state and federal 
agencies will be needed to support these efforts.
The role of decision analysis in the context of newborn screening for rare conditions is likely 
to differ from the application of decision analysis to more common conditions. The scarcity 
of data, particularly for long-term outcomes, will likely result in a much greater reliance on 
expert opinion for the development of modeling inputs and in greater uncertainty for 
modeling results. Despite the greater uncertainty that is likely to be associated with newborn 
screening simulation models, results from these models can still play an important role in 
providing a range of possible benefits and harms associated with screening alternatives. For 
example, a model could provide an estimate of the range of cases prevented, deaths 
prevented, and/or number of children requiring treatment, as well as other health outcomes, 
for universal screening compared to clinical ascertainment. Estimating plausible ranges for 
even a small set of key outcomes could provide useful context for clinical and policy 
decisions.
The role that cost-effectiveness evidence will play in newborn screening policy is still 
evolving, given that there has been so little evidence to date. The charge of the Secretary’s 
Advisory Committee on Heritable Disorders in Newborns and Children currently includes 
cost-effectiveness analysis as one category of evidence to be considered by the Committee, 
but it is only one of several criteria considered by the Committee. The threshold for 
determining whether or not an intervention is cost-effective is not clearly identified in the 
United States and will likely vary with characteristics of the intervention and target 
population.26,27 More broadly, the role of cost-effectiveness analysis in the context of the 
Affordable Care Act is unclear.53 In similar policy contexts, such as the consideration of 
new vaccines by the Advisory Committee on Immunization Practices, cost-effectiveness 
evidence is also one of the categories of evidence considered in policy decisions.
SUMMARY
This review summarizes the approach and data needs for conducting decision analytic 
modeling and economic evaluations of newborn screening programs. In addition to data 
needs that have been identified for long-term follow-up,54 this review identifies additional 
areas to be considered for primary data collection in long-term studies of newborn-screened 
conditions, such as in the design of prospective cohort studies, and other large-scale data 
collection efforts. As newborn screening programs continue to expand, the collection of 
long-term data on newborn-screened conditions could be valuable for informing the 
evaluation of new candidate conditions that share characteristics of currently screened 
conditions. In addition to collection of long-term data on health outcomes, the scarcity of 
data on the costs of screening, follow-up, treatment, and long-term disability must be 
addressed to improve the evaluation process for nominated conditions. Decision analyses 
and economic evaluations can help inform policy decisions for newborn screening programs. 
Prosser et al. Page 12













However, current data limitations have restricted the availability of high-quality evaluations 
for currently screened and candidate conditions.
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Figure 1. Simplified schematic of simulation model to project clinical and economic outcomes for 
PKU using one of many possible screening algorithms
1Or “positive screen”; 2based on additional follow-up, newborns with initial presumed 
diagnoses are eventually categorized as either “false positive” or “true positive”; 3children 
without PKU follow natural history of general population; 4diagnosed through clinical 
identification. PKU, phenylketonuria.
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Table 1




Measurement of health 
benefits Description of health benefits
Decision analysis None Health outcomes, including 
QALYs
Clinical end points or QALYs
Cost-effectiveness analysis Dollars Health outcomes Clinical end points, such as cases averted, 
hospitalizations averted, or deaths averted
Cost–utility analysis Dollars QALYs QALYs incorporate morbidity and mortality effects into 
a single metric
Cost–benefit analysis Dollars Dollars Dollars (typically measured via willingness-to-pay 
survey questions)
QALYs, quality-adjusted life years.
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Table 2
Categories and definitions for required data inputs
Category Subcategory Specific components Description/examples
Clinical outcomes (probabilities) Screening phase Screening outcomes Data on sensitivity, specificity, and 
duration of time for following up test 
results
Medical evaluation phase 
and clinical outcomes
Natural history Epidemiologic data for short- and long-
term outcomes for the condition 
identified via clinical identification or 
with newborn screening; includes 
incidence of condition, mortality rates
Treatment characteristics Estimates of the effectiveness of 
treatment for short- and long-term 
health outcomes; adherence rates; 
adverse events
Costs Screening phase Test costs Cost of the initial screen
Medical evaluation phase Costs of following up out-of-range 
test result
All costs associated with medical 
evaluation following an out-of-range 
test result
Treatment Direct medical costs Hospitalizations, outpatient visits, drug 
treatments, procedures, diagnostic tests, 
medical equipment, other costs
Direct nonmedical costs Transportation costs, special education, 
home modifications, other costs
Opportunity costs Patient time for testing and treatment, 
informal caregiver time
Valuation of health outcomes Screening results Public or parent values for false-positive 
results as valued using QALYs
Health outcomes Public or parent/patient values for short- 
and long-term health outcomes included 
in the natural history model as valued 
using QALYs
Treatments Loss in health-related quality of life 
associated with treatment regimens 
measured using QALYs. Loss in health-
related quality of life could include 
difficulty of adhering to dietary 
treatments or losses in relation to 
painful and difficult transplant 
procedures.
Treatment-related adverse events Loss in health-related quality of life for 
adverse events associated with 
recommended treatment regimens 
measured using QALYs
QALYs, quality-adjusted life years.
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